نبذة مختصرة : Salah Mohamed El Sayed1– 4 1Al-Hijamah Clinic, Medical University Center, College of Medicine, Taibah University, Al-Madinah Al-Munawwarah, Saudi Arabia; 2Department of Clinical Biochemistry & Molecular Medicine, Taibah College of Medicine, Taibah University, Al-Madinah Al-Munawwarah, Saudi Arabia; 3Department of Medical Biochemistry, Faculty of Medicine, Sohag University, Sohag, Egypt; 4Prophetic Medicine Course & Research, Taibah College of Medicine, Taibah University, Al-Madinah Al-Munawwarah, Saudi ArabiaCorrespondence: Salah Mohamed El Sayed, Department of Clinical Biochemistry & Molecular Medicine, Taibah College of Medicine, Taibah University, Al-Madinah Al-Munawwarah, Saudi Arabia, Tel +966-54-2927-804 ; +2-0934-602-963, Email salahfazara@yahoo.comAbstract: Viral hepatitis progresses to liver cirrhosis and HCC. Several challenges are facing Sovaldi treatment to viral C hepatitis, eg, viral resistance, difficulty to treat all genotypes, and inability to access treatments in low-income countries. Also, current treatments to Hepatitis B are still challenging. Ideal treatments to viral hepatitis should decrease the viral load, enhance antiviral immunity and repair the viruses-induced tissue damage. That is still beyond reach. High serum ferritin in viral hepatitis correlates with chronicity, increased necro-inflammation, hepatotoxicity, progression to cirrhosis, progression to HCC, unresponsiveness to treatments and viremia. Previously, Al-hijamah (wet cupping therapy of prophetic medicine) significantly cleared thalassemic children of causative pathological substances (CPS), eg, excess ferritin, free radicals and serum lipids. Moreover, Al-hijamah significantly increased the antioxidant power and potentiated the natural antiviral immunity, eg, increasing CD4 count, CD8 count and CD4/CD8 ratio. Prophet Muhammad peace be upon him said: “If there is a benenvolence (benefit) in any of your medicines, benefit will be in shrtat mihjam (Al-hijamah), honey drink, and a stinge of fire compatible with ...
No Comments.